study subjects. Several strategies for overcoming the challenge of establishing bioequivalence (BE) for highly variable drugs (HVDs; drugs having within-subject variability > 0.3) have been considered in recent years…
extent of absorption. Concerns have been expressed increasingly regarding the difficulty for highly variable drugs and drug products (%CV greater than 30) to meet the standard bioequivalence (BE) criteria using
bioequivalence studies of highly variable drugs, intra-individual variability is usually greater than in other studies (CVw>30%). This makes it necessary to significantly increase the number of subjects ... rule out…
belong to class IV of biopharmaceutical classification system and falls in category of highly variable drugs. A controlled release formulation of ITCZ has been developed in the form of mucoadhesive
Cmax passed the 80-125 % limit range in both drugs for all phase combinations, even though Cmax variability was shown high for clavulanic acid. However, individual bioequivalence was shown ... variability of highly…
generic (Test) and brand name (Reference) formulations of drugs with steep exposure-response relationships exhibiting high pharmacokinetic (PK) variability such as dabigatran represent an expensive challenge for…
highly variable drugs. This has been point of discussion in many conferences and meetings. But to date there is no as such regulatory definition for these drugs or drug products ... suitability of conventional BE…
study design, sample size, study condition, pharmacokinetic parameters, statistical analysis, narrow therapeutic index drugs, highly variable drug products and BCS based bio waiver requirements. The rationale for this…
proposed by the U.S. Food and Drug Administration (FDA) for the evaluation of highly variable drugs. The new approach recommends use of scaled average bioequivalence based on research conducted
variable (HV) drugs products, the new ?all BE studies? rule and some recommendations for improving BE data quality. For locally-acting drug products, since plasma concentrations may not reflect drug ... been expressed…
industry is developing several TDDS for drugs used in elderly, children, chronic illness etc. Bioavalability with transdermals poses certain challenges such as variability, physicological differences and formulation…
thereby optimizing individual dosing regimens. Primarily to monitor drugs with narrow therapeutic ranges, drugs with highly variable pharmacokinetics, drugs with difficult to monitor target concentrations, and drugs…
rate and extent of absorption. However, concerning the wider equivalence criteria for highly variable drug (EMEA, 2008), the test product is bioequivalent to the reference formulation in terms of rate
assumed to distribute relatively homogeneously from plasma to tumor tissues. However, distributionrnof drug in tumors is highly variable and may not correlate with dose or plasma concentrations. Solid tumors ... dense…
using fish oil and flax seed oil by melting emulsification coupled with high shear homogenization technique. Variable drug/polymer ratios in nine different batches were taken to identify the suitable